Immatics (NASDAQ:IMTXW) Short Interest Update

Immatics (NASDAQ:IMTXW) was the recipient of a significant drop in short interest in September. As of September 30th, there was short interest totalling 1,300 shares, a drop of 13.3% from the September 15th total of 1,500 shares. Based on an average trading volume of 800 shares, the days-to-cover ratio is currently 1.6 days.

Immatics Price Performance

NASDAQ IMTXW traded up $0.04 during trading hours on Wednesday, hitting $1.20. The company’s stock had a trading volume of 100 shares, compared to its average volume of 8,117. Immatics has a 12 month low of $0.87 and a 12 month high of $4.14. The company’s 50 day simple moving average is $2.36 and its two-hundred day simple moving average is $2.68.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.